Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
04:30am, Saturday, 07'th Jun 2025
The premise makes enough basic sense -- dividend income is good, so more dividend income is better. Therefore, if you want dividend income, make a point of buying higher-yielding stocks.
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
01:56pm, Thursday, 05'th Jun 2025
Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
06:45am, Wednesday, 04'th Jun 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference.
Is Merck Stock About To Crash?
08:25am, Tuesday, 03'rd Jun 2025
Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average reven
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
05:08pm, Monday, 02'nd Jun 2025
Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
02:51pm, Monday, 02'nd Jun 2025
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
11:56am, Monday, 02'nd Jun 2025
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
10:00am, Monday, 02'nd Jun 2025
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, r
Merck Stock's Ticking Keytruda Time Bomb
09:20am, Monday, 02'nd Jun 2025
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is l
2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away
07:30am, Monday, 02'nd Jun 2025
Even pros can't beat the market. Forecasts fail, fees pile up, and short-term thinking hurts returns. So I stick to quality dividend stocks. I found two high-conviction dividend stocks that the market
Top 10 High-Yield Dividend Stocks
11:44pm, Sunday, 01'st Jun 2025
The liberation day market selloff has been entirely recovered during the month of May. Since inception, my watchlist has a CAGR of 14.81%, performing in-line with SPY and VYM, while providing a superi
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) red
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
12:23pm, Friday, 30'th May 2025
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label Phase 1 KANDLELIT-
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Zilovertamab Vedotin Plus SOC Showed Promising Antitumor Activity, Complete Response Rate, in Relapsed/Refractory DLBCL in waveLINE-003 Trial.
